GLP-1 Tablet Composition for pH-Dependent Solubility Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
GLP1RA, a GLP-1 receptor agonist, is poorly permeable and poorly soluble with a strong pH-dependent solubility profile, leading to variability in absorption and potential food effects, necessitating a composition that enhances solubility and dissolution rate while minimizing drug-drug interactions and food effects.
Innovation Solution
A tablet composition comprising GLP1RA or its pharmaceutically acceptable salt, such as GLP1RA-Ca, combined with a pH modifier like sodium carbonate, super disintegrant (e.g., croscarmellose sodium or crospovidone), and lubricant (e.g., magnesium stearate), along with an SDD preparation using PVP-VA to maintain an amorphous state, ensuring effective delivery to the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP1RA is formulated as a conventional solid oral dosage form, then the tablet is easy to manufacture and swallow, but the solubility and dissolution rate are poor leading to variable absorption
Solution Approach 1:
The patent applies particle size reduction to change the physical parameters of GLP1RA from conventional crystalline form to fine amorphous particles. This parameter change increases surface area and dissolution rate, thereby improving absorption reliability while maintaining manufacturability through spray-drying techniques
Solution Approach 2:
The patent creates a composite tablet formulation combining GLP1RA particles with pH modifiers (calcium carbonate, magnesium carbonate, sodium bicarbonate, or sodium carbonate) and disintegrants. This composite structure enhances solubility and dissolution characteristics, resolving the contradiction between absorption reliability and formulation simplicity
2Ease of operation
If GLP1RA is administered with food or water, then patient compliance is improved, but food effects and drug-drug interactions increase due to pH-dependent solubility
Solution Approach 1:
The patent introduces pH modifiers as intermediary substances that buffer the gastric environment. These modifiers (calcium carbonate, magnesium carbonate, sodium bicarbonate, or sodium carbonate) maintain optimal pH for GLP1RA dissolution and absorption, reducing food effects and drug-drug interactions while allowing flexible dosing with or without food
Solution Approach 2:
The patent changes the solubility parameter profile of GLP1RA by formulating it with pH modifiers that maintain a broader pH range. This parameter change reduces pH-dependent solubility variability, thereby minimizing food effects and enabling easier operation without strict dietary restrictions
3Ease of operation
If the tablet size is reduced to facilitate patient swallowing, then ease of administration is improved, but the amount of active substance that can be delivered is reduced
Solution Approach 1:
The patent segments the GLP1RA active substance into fine amorphous particles through spray-drying and particle size reduction. This segmentation allows the total active substance to be distributed throughout a small tablet volume, maintaining both small tablet size for easy swallowing and adequate drug delivery quantity
Solution Approach 2:
The patent changes the physical state and particle size parameters of GLP1RA from conventional crystalline form to fine amorphous particles. This parameter change increases the concentration of active substance per unit volume, enabling adequate drug delivery in small tablet sizes that are easy to swallow
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides reliable pharmacokinetic performance with minimal food effects, facilitating patient-friendly dosing without water restrictions, suitable for treating type 2 diabetes and weight management.
Implementation Method 1
combined with a pH modifier like sodium carbonate
Implementation Method 2
SDD preparation using PVP-VA to maintain an amorphous state
Data Source
AI summary
Disclosed herein is a tablet composition comprising 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and a pH modifier. In one embodiment, a tablet composition comprises a spray dried dispersion (SDD) of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, wherein the SDD also comprises a polymer to maintain an amorphous state.